Valneva (VALN) has released an update.
Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable turnaround to a €24.7 million net profit, driven by strong product sales and a successful private placement. The company is progressing with the launch of its chikungunya vaccine in Canada and Europe, and anticipates further approvals in Brazil and the UK. With a promising pipeline, including the S4V2 Shigella vaccine candidate, Valneva is poised for growth and strategic expansion.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ZGD, HGGG: 2 Gold ETFs with More than 20% Expected Returns, According to Analysts
- Immunic Reports Q3 Earnings and Provides Corporate Update
- Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
